TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00739583
Drug: Iodophor 0.7% and IPA 74% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin preparation of the surgical site per product labeling. The area will be painted with the solution.
Study: NCT00414037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-treatment
Study: NCT02847325
Drug: AC0058TA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA
Study: NCT02847325
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT00643799
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg oral capsule twice daily for 6 months
Study: NCT03828747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.
Study: NCT03828747
Drug: [18F]GTP1
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Study: NCT00643799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched oral placebo for 6 months
Study: NCT04521569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the donor lungs are randomized to the Steen solution arm, the donor lungs will be perfused with placebo at a rate equivalent to the dosage of Regadenoson (1.44 microgram/kg/min), for a minimum of three hours and maximum of four hours, using the same pediatric syringe pump. The infusion will begin within 10 minutes of the start of the EVLP procedure.
Study: NCT01009853
Drug: Codeine Sulfate
Normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg tablet
Study: NCT02507076
Drug: isolated limb perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo ILP with melphalan
Study: NCT00433940
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
Study: NCT01094808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT01441869
Drug: Diabex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release oral tablets, 1000 mg, single dose
Study: NCT01441869
Drug: Diabex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release oral tablets, 500 mg, single dose
Study: NCT02982395
Drug: Nanoxel®M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical
Study: NCT00431080
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
Study: NCT00431080
Drug: 5-fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
Study: NCT00955253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02874924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: control
Study: NCT00996476
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks
Study: NCT01183234
Drug: SPD544
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 30mg capsules, single oral dose
Study: NCT00889629
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol)
Study: NCT00853190
Drug: Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
Normalized name: chlorpheniramine polistirex / hydrocodone polistirex Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
Study: NCT04521348
Drug: multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody
Normalized name: anti-inhibitor coagulant complex 1 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
Study: NCT00092352
Drug: MK0966, rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003493
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04350593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT00677001
Drug: R306465
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04301531
Drug: Treatment for all cases confirmed positive malaria cases with ACTs
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: During each mass testing, all confirmed positive cases are treated in both arms.
Study: NCT00757588
Drug: Placebo + insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets given orally once daily for 24 weeks (short-term period)+ insulin with metformin
Study: NCT01954966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will consume four pills of Placebo over a period of four days. Participants will be asked to remain abstinent from smoking while taking Placebo.
Study: NCT02078310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Part 2
Study: NCT04325243
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets of the same shape, color and size of Sildenafil tablets manufactured in the Department of Pharmaceuticals, Faculty of Pharmacy
Study: NCT01156792
Drug: GSK2190915 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 100mg QD (AM)
Study: NCT01156792
Drug: GSK2190915 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 300mg QD (AM)
Study: NCT01156792
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo BID
Study: NCT01156792
Drug: FP/SAL 100/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP/SAL 100/50mcg BID
Study: NCT00413023
Drug: GW679769
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00626301
Drug: LPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r 230/57.5 mg/m2 orally q12h or the adjusted dose based on therapeutic drug monitoring of LPV/r prior to enrollment as maintenance monotherapy
Study: NCT03629288
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet containing 500mg Azithromicyn. Procedure: Periodontal treatment Scaling and root planning
Study: NCT01505777
Drug: Probiotics (Medirac)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10/mosapride 10mg three times a day, P.O. 4week
Study: NCT01505777
Drug: Probiotics (Medirac)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15/mosapride 10mg three times a day, P.O. 4week
Study: NCT01505777
Drug: Probiotics (Medirac)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15/mosapride 15mg three times a day, P.O. 4week
Study: NCT01505777
Drug: Probiotics (Medirac)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30/mosapride 15mg three times a day, P.O. 4week
Study: NCT04394598
Drug: Dendrobium Huoshanense Granules
Normalized name: Dendrobium moniliforme whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g tid per day for 5weeks
Study: NCT00577577
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
Study: NCT03032432
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection to improve rotator cuff tendinosis pain and functional score
Study: NCT04394598
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 625mg/m2 bid Monday-Friday per week
Study: NCT06485453
Drug: Botox 200 UNT Injection
Normalized name: Botox 200 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effect and duration of Onabotulinum Toxin A according to patient's pad usaged
Study: NCT00073866
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00496769
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, oral, 81-324 mg, once daily, up to 156 weeks
Study: NCT00230035
Drug: Growth colony stimulating factor (G-CSF)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00230035
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00230035
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00230035
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04643132
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the induction of anesthesia, normal saline is intravenously injected in a volume of 2ml, and then a continuous infusion of 20ml/h normal saline until starting skin suture.
Study: NCT06135181
Drug: Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mmol Gd/kg by intravenous injection (at 2 mL/s)
Study: NCT06135181
Drug: Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mmol Gd/kg by intravenous injection (at 2 mL/s)
Study: NCT06135181
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride by intravenous injection (at 2 mL/s)
Study: NCT03723252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo po qd
Study: NCT03622762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, 400 mg twice daily fasting
Study: NCT00454961
Drug: artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00260156
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00223717
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Po or patch. Single dose.
Study: NCT00223717
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-100 mg po. Single dose.
Study: NCT01474395
Drug: D-serine
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
Study: NCT04532554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injection with the same amount
Study: NCT01474395
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
Study: NCT01980953
Drug: GDC-0032 Phase III Tablet
Normalized name: CARDIOTOXIN III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.
Study: NCT03478423
Drug: Codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
Study: NCT04737187
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken by mouth two times a day, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest
Study: NCT00760773
Drug: Lacidophil (experimental standard dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
Study: NCT00760773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
Study: NCT02273401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02455154
Drug: Zhongyaofufang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine for patients with Osteoporosis
Study: NCT02455154
Drug: Xianlinggubao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine for patients with Osteoporosis
Study: NCT02772419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC administration
Study: NCT00785083
Drug: FTY720
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00785083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02022358
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (12 g/m2 x 1, intravenously)
Study: NCT04068766
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study: NCT02110719
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02110719
Drug: oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02110719
Drug: oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01082029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
Study: NCT03541174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet
Study: NCT04556292
Drug: SC10914
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC10914 400mg tid
Study: NCT00903604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 10-minutes infusions of isotonic saline solution
Study: NCT01827475
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose
Study: NCT01827475
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT01827475
Drug: Ibuprofen-acetaminophen combination
Normalized name: ibuprofen, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT00495053
Drug: hMaxi-K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)
Study: NCT00134745
Drug: estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
Study: NCT02576301
Drug: Phase 1 - OXi4503
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Determination of MTD of OXi4503
Study: NCT04027192
Drug: BAY2328065 LSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/mL LSF (liquid service formulation), orally
Study: NCT04027192
Drug: BAY2328065 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tablet, orally
Study: NCT04027192
Drug: Placebo LSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo LSF, orally
Study: NCT04027192
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo tablet, orally
Study: NCT00416832
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00416832
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04552483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 8/8 hours for 5 days in the early clinical phase of COVID-19.
Study: NCT00650351
Drug: Cipro® XR Tablets 1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg, single dose fed
Study: NCT00641329
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT02351934
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.
Study: NCT00368251
Drug: BRV 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical Form: Tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use
Study: NCT00368251
Drug: BRV 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical Form: Tablet~* Concentration: 25 mg~* Route of Administration: Oral use
Study: NCT00368251
Drug: BRV 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical Form: Tablet~* Concentration: 50 mg~* Route of Administration: Oral use
Study: NCT03740464
Drug: long-acting granulocyte colony stimulating factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group
Study: NCT03210740
Drug: AM001 Cream, 7.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Cream
Study: NCT03210740
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placeo
Study: NCT03350386
Drug: FYU-981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration
Study: NCT03350386
Drug: Oxaprozin
Normalized name: Oxaprozin
DrugBank: Oxaprozin (DB00991)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeated administration
Study: NCT02121301
Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: eyedrops
Study: NCT00930020
Drug: Minocycline (Borymycin)
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral dose, 200 mg once a day for 5 days
Study: NCT00930020
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo (cornstarch) once a day for 5 days
Study: NCT00183339
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Between 2 mg per day and 20 mg per day of liquid fluoxetine will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
Study: NCT02121301
Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: eyedrops
Study: NCT02121301
Drug: Placebo (Vehicle) opthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: eyedrops
Study: NCT03350477
Drug: Life information rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study: NCT03147092
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of hypertensive subjects
Study: NCT00183339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Between 0.5ml per day and 5ml per day of liquid placebo will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
Study: NCT00526474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching tablet daily for at least 1 year
Study: NCT02891590
Drug: DTRMWXHS-12
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02809027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02579499
Drug: fixed high potent statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned fixed high-potent statin group will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels, and maintain high-intensity statin therapy regardless of their follow-up LDL-C level.